

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

MEK1/2 (L38C12) Mouse mAb

RRID:AB_10695868

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4694, RRID:AB_10695868

Antibody Information

URL: http://antibodyregistry.org/AB_10695868

Proper Citation: Cell Signaling Technology Cat# 4694, RRID:AB_10695868

Target Antigen: MEK1/2 (L38C12) Mouse mAb

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC, F. Consolidation on 10/2018: AB_10695868, AB_390778.

Antibody Name: MEK1/2 (L38C12) Mouse mAb

Description: This monoclonal targets MEK1/2 (L38C12) Mouse mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_10695868

Vendor: Cell Signaling Technology

Catalog Number: 4694

Record Creation Time: 20250820T011925+0000

Record Last Update: 20250820T103724+0000

Ratings and Alerts

No rating or validation information has been found for MEK1/2 (L38C12) Mouse mAb.

No alerts have been found for MEK1/2 (L38C12) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sang B, et al. (2026) Disrupted molecular glue complex drives RAS inhibitor resistance. *Cell*, 189(10), 2918.

Postlmayr A, et al. (2026) Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2 activation. *Cell reports*, 45(3), 117046.

Yuan T, et al. (2026) USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit. *Acta pharmaceutica Sinica. B*, 16(1), 322.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Wang Z, et al. (2026) Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e15158.

Yang C, et al. (2025) KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiquitinase USP25 with RNF31. *Developmental cell*, 60(12), 1768.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. *Cancer research*, 85(1), 118.

Sealover NE, et al. (2025) Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers. *Science signaling*, 18(904), eadx5186.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. *Cancer cell*.

Yang SH, et al. (2024) Activated dormant stem cells recover spermatogenesis in chemoradiotherapy-induced infertility. *Cell reports*, 43(8), 114582.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. *Cancer biology & therapy*, 25(1), 2332000.

Klomp JA, et al. (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. *Science (New York, N.Y.)*, 384(6700), eadk0775.

Kulkarni A, et al. (2024) Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. *EMBO reports*, 25(9), 3944.

Kim S, et al. (2023) Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. *Cell reports*, 42(6), 112570.

Randic T, et al. (2023) Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response. *Cell reports*, 42(7), 112696.

Xia Y, et al. (2023) Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP. *European journal of pharmacology*, 961, 176157.

Song Z, et al. (2023) Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma. *Biochemical pharmacology*, 213, 115612.

Fan Y, et al. (2023) Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy. *Molecular cell*, 83(19), 3520.

Ezzeldin S, et al. (2023) Detection of early prognostic biomarkers for metastasis of Ewing's sarcoma in pediatric patients. *Life sciences*, 334, 122237.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. *Cell reports*, 42(1), 112031.